SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Rhea-AI Summary
SAB Biotherapeutics (Nasdaq:SABS) will present new data on its lead program SAB-142, a fully human multi-specific anti-thymocyte globulin for newly diagnosed Stage 3 type 1 diabetes, at ADA’s 2026 Scientific Sessions and the FOCIS 2026 Annual Meeting in June.
Presentations will cover safety, pharmacokinetics, immunogenicity, pharmacodynamics, mechanistic insights, and long-term repeat dosing, supporting the ongoing registrational Phase 2b SAFEGUARD study, with topline data expected in 2H 2027. Materials will be posted on SAB BIO’s website after the meetings.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – SABS
On the day this news was published, SABS gained 0.84%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SABS was down about 0.83% while 3 momentum peers (e.g., QTTB, AKTX, NRXS) were moving up (median around 5.0%), and one peer, NNVC, was down. This mixed picture and opposite direction vs most peers suggest today’s move was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 2026 earnings | Positive | -2.7% | Reported Q1 results, cash runway through 2028, and FDA surrogate endpoint feedback. |
| May 05 | Earnings call notice | Neutral | -0.3% | Announced timing and access details for the upcoming Q1 2026 results call. |
| Apr 22 | Phase 1 T1D data | Positive | +4.2% | Presented Phase 1 SAB-142 data showing C-peptide preservation and improved glycemic control. |
| Apr 15 | IDS 2026 presentations | Positive | +4.9% | Announced additional SAB-142 clinical and mechanistic data to be shown at IDS 2026. |
| Mar 19 | Public equity offering | Negative | -0.8% | Closed $85M stock and pre-funded warrant offering to fund SAB-142 trials and operations. |
Stock usually trades in line with news tone; only the recent Q1 report saw a negative reaction to broadly positive fundamentals.
Over recent months SABS has focused investors on its SAB-142 program and funding runway. In March 2026, it raised about $85 million in a public offering to support SAB-142 development. An April IDS 2026 update showed Phase 1 data with C-peptide preservation and glycemic improvements, and the stock rose 4.2% and 4.92% on two clinical/data-related events. The Q1 2026 report highlighted cash of $217.6 million and an ongoing Phase 2b SAFEGUARD trial, although shares fell 2.69% after that release. Today’s ADA/FOCIS presentation plans extend this ongoing data-disclosure cadence.
Market Pulse Summary
This announcement highlights upcoming SAB-142 data at the ADA 2026 and FOCIS 2026 meetings, emphasizing deeper mechanistic insights and long-term dosing potential in Stage 3 T1D. It fits a steady cadence of SAB-142 updates following prior IDS 2026 presentations and the registrational Phase 2b SAFEGUARD trial targeting topline data in 2H 2027. Investors may watch for how the new ADA/FOCIS results build on earlier Phase 1 findings and whether they further reinforce the program’s disease-modifying profile and repeat-dosing rationale.
Key Terms
anti-thymocyte immunoglobulin medical
phase 2b medical
pharmacokinetics medical
immunogenicity medical
pharmacodynamics medical
t-cell medical
AI-generated analysis. Not financial advice.
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D
MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it will present data at two congresses in June. SAB BIO will present an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) being held June 5-8, 2026, in New Orleans, LA. The Company will also present a poster presentation at the Federation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting being held June 9-12, 2026, in San Francisco, CA. Data to be presented will highlight SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 T1D patients.
“We are pleased to participate in both ADA’s 2026 Scientific Sessions and FOCIS 2026 to continue engaging with the broader diabetes and immunology communities. These forums provide an important opportunity to highlight SAB-142’s clinical and mechanistic profile and to build further understanding of the potential for this unique multi-specific modality as we advance the program through the ongoing registrational Phase 2b SAFEGUARD study,” said Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO. “We look forward to continuing to collaborate with the scientific community and to advance toward our topline data readout for SAFEGUARD in the 2H 2027.”
Oral Presentation at ADA’s 2026 Scientific Sessions:
Title: Clinical Safety, Pharmacokinetics, Immunogenicity, and Pharmacodynamics following Repeat Dosing of SAB-142, a Fully Human Multi-Specific Antithymocyte Globulin for New-Onset Type 1 Diabetes
Session: Oral Presentations - Preventing Type 1 Diabetes
Presenter: Christoph Bausch, PhD, MBA, Chief Operating Officer, SAB BIO
Presentation Date and Time: Friday, June 05, 2026, 2:45 - 3:00 PM CT
Location: New Orleans Convention Center – Session Room 245 (Level 2)
Poster Presentation at FOCIS 2026 Annual Meeting:
Title: Positive Clinical Translation of a Juvenile NHP Study for Evaluating SAB-142, a Multi-Specific T-Cell Targeting T1D Therapy, in Humans
Session: Exhibit and Poster Reception – Poster # W114
Presenter: Diane Maher, PhD, Director, Program Management, SAB BIO
Presentation Date and Time: Wednesday, June 10, 2026, 6:50 - 8:05 PM PT
Location: San Francisco Marriott Marquis – Discovery Center Poster & Exhibit Hall – Salon 9
The presentations will be made available in the Presentations section of the Company’s website afterwards and will remain accessible following the conference.
About SAB-142
SAB-142 is a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new- or recent-onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of “bad acting” T-lymphocytes. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.
Forward-Looking Statements
Certain statements made in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company’s T1D program and other discovery programs.
These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
CONTACTS
Investor Relations:
Christine Ryan
ir@sab.bio
Media:
Sheila Carlson
media@sab.bio
